Topics

United Therapeutics' Small Cell Lung Cancer Study Primary Endpoint Not Meet

06:35 EST 3 Feb 2020 | RTTNews

United Therapeutics Corp. (UTHR) announced Monday topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin (dinutuximab) Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory small cell lung cancer (SCLC).

Original Article: United Therapeutics' Small Cell Lung Cancer Study Primary Endpoint Not Meet

NEXT ARTICLE

More From BioPortfolio on "United Therapeutics' Small Cell Lung Cancer Study Primary Endpoint Not Meet"

Quick Search

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...